2607 — Shanghai Pharmaceuticals Holding Co Balance Sheet
0.000.00%
- HK$43.80bn
- HK$69.71bn
- CNY275.25bn
- 57
- 96
- 90
- 96
Annual balance sheet for Shanghai Pharmaceuticals Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 22,228 | 22,204 | 36,852 | 38,697 | 42,254 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 57,719 | 63,759 | 73,225 | 81,948 | 86,539 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 107,563 | 116,494 | 149,513 | 162,434 | 171,823 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14,856 | 16,128 | 16,542 | 18,279 | 19,305 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 149,186 | 163,436 | 198,135 | 211,973 | 221,209 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 88,133 | 91,824 | 110,691 | 122,372 | 126,038 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 103,831 | 114,076 | 131,072 | 143,448 | 149,534 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 45,355 | 49,359 | 67,063 | 68,524 | 71,676 |
| Total Liabilities & Shareholders' Equity | 149,186 | 163,436 | 198,135 | 211,973 | 221,209 |
| Total Common Shares Outstanding |